Alnylam Pharmaceuticals (ALNY) PT Lowered to $415 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $162.36 +1.54%
Rating Summary:
26 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
26 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
H.C. Wainwright analyst Patrick Trucchio lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $415.00 (from $430.00) while maintaining a Buy rating.
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $199 at Bernstein SocGen Group
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
- Camtek (CAMT) PT Lowered to $140 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
